Stockscreener 앱 받기
1.75
0.57%
-0.01
시간 외 거래:
1.75
전일 마감가:
$1.76
열려 있는:
$1.87
하루 거래량:
27,672
Relative Volume:
3.23
시가총액:
$54.66M
수익:
-
순이익/손실:
-
주가수익비율:
-0.6945
EPS:
-2.5197
순현금흐름:
-
1주 성능:
+3.55%
1개월 성능:
+16.67%
6개월 성능:
-24.55%
1년 성능:
-26.16%
1일 변동 폭
$1.72
$1.88
1주일 범위
$1.70
$1.88
52주 변동 폭
$1.10
$3.89
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
ANL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
1.75 | 64.94M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | 개시 | H.C. Wainwright | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr 주식(ANL)의 최신 뉴스
What machine learning models say about Adlai Nortye Ltd. Depositary ReceiptTrade Performance Summary & Verified Chart Pattern Trade Signals - Newser
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Selloffs & Trade Opportunity Analysis Reports - Newser
Live market analysis of SPAIJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Key resistance and support levels for Adlai Nortye Ltd. Depositary ReceiptJuly 2025 Final Week & Fast Gain Stock Tips - Newser
Candlestick signals on FBGL stock todayForecast Cut & Stock Market Timing Techniques - Newser
F.N.B. Corporation stock trendline breakdownJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - Newser
Is Brookfield Asset Management Ltd. stock reversal real or fake2025 Price Action Summary & Reliable Price Breakout Alerts - Newser
How to use a screener to detect IROHW breakouts2025 Risk Factors & Expert Curated Trade Setups - Newser
Analyzing drawdowns of Coeptis Therapeutics Holdings Inc. with statistical toolsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Is GSK plc ADRhedged forming a bottoming base2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Trend analysis for Intercontinental Exchange Inc. this weekWeekly Risk Report & Reliable Intraday Trade Alerts - Newser
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Long term hold vs stop loss in CEADJuly 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Adlai Nortye (NASDAQ:ANL) Stock Price Up 3.2% – Should You Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
AlphaTime Acquisition Corp Debt Equity Composite Units recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
Comparing Adlai Nortye Ltd. Depositary Receipt in custom built stock radarsDaily Upside Movement Prediction With Data - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Adlai Nortye Ltd. Announces 2025 Share Incentive Plan and Board Changes - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – Here’s What Happened - Defense World
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS By Investing.com - Investing.com South Africa
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS - Investing.com
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Adlai Nortye to present at AACR Annual Meeting with two abstracts scheduled. - AInvest
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye stock strengthened by oncology trial results, H.C. Wainwright keeps at Buy list - Investing.com India
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
Adlai Nortye Announces 2.5M ADS IPO at $23/sh - Investing.com
CRVO Stock Quote Price and Forecast - CNN
Adlai Nortye Ltd Adr (ANL) 재무 분석
Adlai Nortye Ltd Adr (ANL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):